Downside To Cutting-Edge Treatment: High Costs Leave Some Patients Out
Thursday, April 25, 2013 - 11:01
in Health & Medicine
Chronic myeloid leukemia (CML) is now considered a highly curable disease, thanks to the emergence of powerful, targeted CML therapies known as tyrosine kinase inhibitors (TKIs) that allow patients to manage their disease with few symptoms by taking a well-tolerated pill. Since the introduction of TKI therapy more than a decade ago, the annual mortality of patients with this disease has declined from 10 to 20 percent in the early 2000s to just 2 percent today and the estimated 10-year survival of CML patients has increased from 20 percent to more than 80 percent. read more